Our advisory board.
Our compass and mirror.
With our advisory board, we rely on the opinions of renowned scientists and experts. This allows us to be sure that a broad spectrum of ideas and perspectives are incorporated into our decisions.
Their experience and expertise help us every day in the research and development of complex next-generation pharmaceuticals for our customers.
Marina Heimann, LL.M., is a strategy and governance expert with a background in banking and business administration. With over 20 years of experience in business, the public sector, and start-up ecosystems, she supports growth, transformation, and organizational development. As an entrepreneur, supervisory board member/advisory board member, and investor, she combines corporate governance, risk & compliance, and innovation management—and promotes sustainable impact. Her network ranges from industry and research to politics and regional innovation players.
Stanislaw Tillich was Minister President of the State of Saxony from 2008 to 2017.
With extensive experience in politics, business, and European cooperation, he brings strategic foresight for sustainable innovation and location development.
At CUP, he helps to strengthen the dialogue between science, industry, and politics—as a basis for competitiveness and long-term growth.
Prof. Dr. med. Dr. Esther Troost, specialist in radiation oncology, heads the Clinic and Polyclinic for Radiation Therapy and Radiation Oncology at TUD Dresden University of Technology, is also responsible for the field of image-guided radiation oncology at the Helmholtz Center Dresden-Rossendorf, is involved in national and international expert committees, conducts research into the further development of precise, image-guided radiation therapy, and regularly publishes in high-ranking specialist journals. Since 2022, she has also been Dean of the Medical Faculty at TU Dresden.
Dr. Gabriele Wanninger is a licensed pharmacist and a proven expert in regulation and quality assurance in the pharmaceutical industry. Since 1988, she has worked in state drug testing and monitoring, conducted GMP/GDP/GCP inspections, and headed the pharmacy department at the government of Upper Bavaria for 16 years. Since February 2023, she has been a senior consultant and lead auditor at PharmaKorell GmbH, assisting companies with inspections, compliance issues, and global regulatory strategies.
Dr. Helmut Wolf is a chemist and process engineer with decades of experience in the pharmaceutical industry. He has held senior positions in development and production at international companies, including as managing director of Lyocontract GmbH. Today, he advises pharmaceutical and biotech companies on efficient processes, quality strategies, and sustainable growth. His expertise and strategic vision strengthen CUP's further development as a reliable analytics and innovation partner.
Our research projects
for a better future.
We are actively working to realize our vision with a great deal of passion and expertise.
Alliance RUBIN.
SNRT – Saxon Network for Radionuclide Theranostics.
The aim of the SNRT project is to develop Dresden into a leading innovation location in Europe for radionuclide theranostics, a field that combines diagnostic and therapeutic radiopharmacy. The project aims to develop new radiopharmaceuticals and improve the production processes of radionuclides in order to offer efficient and cost-effective medical solutions.
Unique to look at: The cyclotron from the HZDR.
A project funded by the German Federal Ministry of Education and Research (BMBF).
